What is pharmacogenetics and what is pharmacogenomics?
What is pharmacogenetics and what is pharmacogenomics?
The terms pharmacogenetics and pharmacogenomics are frequently used in personalized medicine literature. While there is no definitive consensus on their definitions, there are certain features of each field that are both distinct and overlapping. Pharmacogenomics is a term introduced in late 1990s and is broadly defined as a field of study on variability in therapeutic and toxic effects of drugs using information from the entire genome of an individual. Person-to-person variations in both gene sequence and gene expression are considered in pharmacogenomics studies. By contrast, the term pharmacogenetics has been established since 1950s and refers to investigations on specific candidate genes in relation to individual differences in drug side effects and effectiveness.
Candidate genes in pharmacogenetics studies are selected based on established or postulated mechanisms of disease susceptibility, drug absorption, metabolism, transport and excretion as well as knowledge of drug targets (the cellular or extracellular molecules which bind drugs and play a pivotal role in producing the clinically observable drug effects). On the other hand, pharmacogenomics adopts a broader genome-wide and hypothesis-free approach.
Despite these notable differences, there is also interdependency between the two fields. Once the genes or genetic markers relevant to mechanism of drug action or side effects are identified through the genome-wide pharmacogenomics search, each individual gene requires further clinical validation by focused and hypothesis-driven pharmacogenetics approaches before they can be routinely applied at point of care in the clinic. We herein chose to use the term pharmacogenomics but many of the ensuing discussion and concepts on this website will also be applicable to pharmacogenetics.
Modified from Ozdemir and Lerer (2005) "Pharmacogenomics and the promise of personalized medicine". In: Pharmacogenomics, Second Expanded Edition. Kalow W, Meyer UA, Tyndale RF (Editors), Francis & Taylor: New York, pp. 13-50.
Bailey, D.S., Bondar, A., Furness, L.M. Pharmacogenomics - it's not just pharmacogenetics. Curr Opin Biotechnol 1998; 9(6): 595-601.
Bertilsson, L., Alm, C., De Las Carreras, C., Widen J., Edman G., Schalling D. Debrisoquine hydroxylation polymorphism and personality. Lancet 1989; 1(8637): 555.
Eichelbaum, M., Spannbrucker, N., Dengler, H.J. Lack of N-oxidation of sparteine in certain healthy subjects. Sixth International Congress of Pharmacology, Helsinki, July 20-25, 1975; 1071.
Eichelbaum, M., Spannbrucker, N., Steincke, B., Dengler, H.J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183-87.
Evans, D.A., Manley, K.A., McKusick, V.A. Genetic control of isoniazid metabolism in man. BMJ 1960; 2: 4484-91.
Gonzalez, F.J., Skoda, R.C., Kimura, S., Umeno, M., Zanger, U.M., Nebert, D.W., Gelboin, H.V., Hardwick, J.P., Meyer, U.A. Characterization of the common genetic-defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-46.
Gurwitz, D., Motulsky, A.G. 'Drug reactions, enzymes, and biochemical genetics': 50 years later. Pharmacogenomics 2007; 8: 1479-84.
Hopkins, M.M., Ibarreta, D., Gaisser, S., Enzing, C.M., Ryan, J., Martin, P.A., Lewis, G., Detmar, S., van den Akker-van Marle M.E., Hedgecoe, A.M., Nightingale, P., Dreiling, M., Hartig, K.J., Vullings, W., Forde, T. Putting pharmacogenetics into practice. Nat Biotechnol 2006; 24(4): 403-10.
Kalow, W. (1962) Pharmacogenetics. Heredity and the Response to Drugs. W. B. Saunders Co., Philadelphia, London.
Mahgoub, A., Idle, JR, Dring, L.G., Lancaster, R., Smith, R. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2, 584-6.
Masimirembwa, C.M., Johansson, I., Hasler, J.A., Ingelman-Sundberg, M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993; 3: 275-80.
Masimirembwa, C., Persson, I., Bertilsson, L., Hasler, J., Ingelman-Sundberg, M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42: 713-19.
Motulsky, AG. Drug reactions, enzymes and biochemical genetics. JAMA 1957; 165: 835-37.
Nebert, DW. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist? Clin Genet 1999; 56: 247-58.
Nebert, D.W., Zhang, G., Vesell, E.S. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008; 40: 187-224.
Ozdemir, V., Lerer, B. Pharmacogenomics and the promise of personalized medicine. In: Pharmacogenomics, Second Expanded Edition; 2005. Kalow W, Meyer UA, Tyndale RF (Editors), Francis & Taylor: New York, pp. 13-50.
Ozdemir, V., Kalow, W., Tothfalusi, L., Bertilsson, L., Endrenyi, L., Graham, J.E. Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions. Curr Pharmacogenomics Person Med 2005; 3, 53-71.
Pirmohamed, M. Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol 2001; 52: 345-47.
Vogel, F. Moderne problem der humangenetik. Ergeb Inn Med U Kinderheilk 1959; 12: 52-125.
Wilke, R.A., Mareedu, R.K., Moore, J.H. The pathway less traveled: Moving from candidate genes to candidate pathways in the analysis of genome-wide data from large scale pharmacogenetic association studies. Curr Pharmacogenomics Person Med 2008; 6(3): 150-59.
Publication Inclusion and Exclusion in Nutrigenetics Clinical Research: Ethical and Scientific Challenges
An article by Hurlimann T, Stenne R, Menuz V and Godard B published in the Journal of Nutrigenetics and Nutrigenomics 2011; 4(6). Online first. There are compelling reasons to ensure the participation of ethnic minorities and... Read more
An article by Hurlimann T, Stenne R, Menuz V and Godard B published in the Journal of Nutrigenetics and Nutrigenomics 2011; 4(6). Online first. There are compelling reasons to ensure the participation of ethnic minorities and populations of all ages worldwide in nutrigenetics clinical research. If findings in such research are valid for some individuals, groups, or communities, and not for others, then ethical questions of justice – and not only issues of methodology and external validity – arise. This paper aims to examine inclusion in nutrigenetics clinical research and its scientific and ethical challenges. For more information, click here.
Publication Is Human Enhancement also a Personal Matter?
An article by Vincent Menuz, Thierry Hurlimann and Béatrice Godard, published in Science and engineering ethics, online first (2011) DOI:Read more
An article by Vincent Menuz, Thierry Hurlimann and Béatrice Godard, published in Science and engineering ethics, online first (2011) DOI:10.1007/s11948-011-9294-y. This paper proposes a timely and much needed examination of the various definitions of human enhancement found in the literature and proposes a definition of human enhancement that focuses on individual perceptions. While acknowledging that a definition that mainly depends on personal and subjective individual perceptions raises many challenges, the authors suggest that a comprehensive approach to define human enhancement could constitute a useful premise to appropriately address the complexity of the ethical and social issues it generates. For a full abstract and paper, click here.
